



Aerpio Pharmaceuticals to Announce Second Quarter 2018 Financial Results and Host Conference Call on Tuesday, August 14, 2018

August 7, 2018

CINCINNATI--(BUSINESS WIRE)--Aug. 7, 2018-- Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that its second quarter 2018 financial results will be released before the market opens on Tuesday, August 14, 2018. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. Eastern Time to discuss the Company's financial results and provide a general business update.

The live webcast and a replay may be accessed by visiting Aerpio's website at <http://ir.aerpio.com/>. Please connect to the Company's website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call (877) 216-7943 (U.S.) or (417) 629-5045 (international) to listen to the live conference call. The conference ID number for the live call is 1372519. Please dial in approximately 10 minutes prior to the call. Telephone replay will be available approximately two hours after the call. To access the replay, please call (855) 859-2056 (U.S.) or (404) 537-3406 (international). The conference ID number for the replay is 1372519.

About Aerpio Pharmaceuticals

Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases. The Company's lead compound, AKB-9778, is a small molecule activator of the Tie2 pathway and is in clinical development for the treatment of non-proliferative diabetic retinopathy.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180807005243/en/>

Source: Aerpio Pharmaceuticals, Inc.

Investors & Media:

Aerpio Pharmaceuticals, Inc.

Michael Rogers

Chief Financial Officer

mrogers@aerpio.com

or

Burns McClellan, on behalf of Aerpio Pharmaceuticals, Inc.

Media:

Robert Flamm, Ph.D.

rflamm@burnsmc.com

or

Investors:

Ami Bavishi

abavishi@burnsmc.com